Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given